PUBLISHER: The Business Research Company | PRODUCT CODE: 1270587
PUBLISHER: The Business Research Company | PRODUCT CODE: 1270587
“Drug Discovery Informatics Global Market Report 2023 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on drug discovery informatics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for drug discovery informatics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The drug discovery informatics market global report ” from The Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
The impact of higher inflation in many countries and the resulting spike in interest rates.
The continued but declining impact of COVID-19 on supply chains and consumption patterns.
Major players in the drug discovery informatics market are Accenture Plc., Certara, Charles River Laboratories Inc., Infosys Ltd., Collaborative Drug Discovery Inc., Eurofins DiscoverX Products, Jubilant Biosys, Selvita, PerkinElmer Inc., International Business Machines Corporation, Boehringer Ingelheim International GmbH, Oracle Corporation, Thermo Fisher Scientific Inc., Albany Molecular Research Inc., and ChemAxon Ltd.
The global drug discovery informatics market is expected to grow from $2.97 billion in 2022 to $3.32 billion in 2023 at a compound annual growth rate (CAGR) of 12.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The drug discovery informatics market is expected to grow to $5.21 billion in 2027 at a CAGR of 11.9%.
The drug discovery informatics market consists of revenues earned by entities by providing literature databases, chemical databases, biological databases, predictive analytics, structures 2D and 3D, pharmacokinetic and pharmacodynamic data analysis, assay data analysis, genomics data analytics, and proteomics data analytics. The market value includes the value of related goods sold by the service provider or included within the service offering. The drug discovery informatics market also includes sales of CI-based (continuous integration) design tools and pharmacophore modelling tools, which are used in providing drug discovery informatics services. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
Drug discovery informatics is the development of systems that can operate more efficiently with such enormous volumes of clinical trial and treatment data. Drug discovery informatics will assist in managing medical information and can make the process of studying and developing successful new treatments faster and more efficient.
North America was the largest region in the drug discover informatics market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug discover informatics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The main services offered in drug discovery informatics include in-house and outsourced. In-house computer or software refers to computer programs in both source and object code form that is relevant to the group's business and are utilized by the company and were produced by the company rather than licensed by third parties. The various modalities include cloud-based systems and in-campus for applications such as data sequencing, molecular docking, identification and validation and target data analysis for end-users such as pharmaceutical companies, contract research organizations and biotechnology companies.
The rising prevalence of various chronic diseases is expected to propel the growth of the drug discovery informatics market going forward. Chronic illnesses are described generically as disorders that persist for a year or longer and need continuing medical treatment, impede everyday activities or both. Drug discovery informatics systems aid in the advancement of chronic illness care by allowing researchers to probe more complex and transient molecular changes that underpin disease progression and drug response, resulting in multi-dimensional models of the entire hierarchical system in healthy, diseased, and treated states. For instance, according to a report published by the World Health Organization, a Switzerland-based agency of the United Nations responsible for international public health, in 2022, non-communicable diseases (NCDs) are expected to kill 41 million people, accounting for 74% of all deaths worldwide. Every year, 17 million people die from an NCD before the age of 70, with low- and middle-income nations accounting for 86% of these premature fatalities. Cardiovascular illnesses kill the most individuals each year (17.9 million), followed by cancer (9.3 million), chronic respiratory disorders (4.1 million), and diabetes (2.0 million, including kidney disease deaths caused by diabetes). Therefore, the rising prevalence of various chronic diseases is driving the drug discovery informatics market.
Technological advancements have emerged as a key trend gaining popularity in the drug discovery informatics market. Major companies operating in the drug discovery informatics market are focused on developing technologically advanced solutions to sustain and strengthen their market position. For instance, in January 2021, Certara Inc., a US-based biosimulation company introduced version 20 of its Simcyp Physiologically-based Pharmacokinetic (PBPK) Simulator platform. It provides new and improved maternal health models, such as measuring medicine performance during pregnancy and lactation. The Simcyp PBPK Simulator enhances clinical trial efficiency and results by modelling and simulating pharmacokinetics (PK) and pharmacodynamics (PD) using virtual patient populations. For biological drug development, it employs the predictive pharmacokinetics of small molecules.
In November 2022, Norstella, a US-based pharmaceutical consultancy services and solutions provider merged with Citeline. This deal will enable Norstella to prioritize fast innovation to lead life sciences firms through the whole drug development process, allowing patients to receive medicines sooner. Citeline is a US-based provider of research and development of pharmaceutical intelligence and offers information on several drug trials.
The countries covered in the drug discovery informatics market report are: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
The drug discovery informatics market research report is one of a series of new reports from The Business Research Company that provides drug discovery informatics market statistics, including drug discovery informatics industry global market size, regional shares, competitors with a drug discovery informatics market share, detailed drug discovery informatics market segments, market trends and opportunities, and any further data you may need to thrive in the drug discovery informatics industry. This drug discovery informatics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.